Astellas Pharma

Latest Headlines

Latest Headlines

Amgen says it's awaiting reimbursement details after Japan Repatha nod

Amgen said that the approval for Repatha (evolocumab) in Japan filed by Amgen Astellas Biopharma K.K., a joint venture with Tokyo-based Astellas Pharma, could be launched within months pending reimbursement details.

Astellas hooks up with NuMedii to continue drug repurposing deal drive

Astellas Pharma has signed its second tech-enabled drug repurposing deal in as many months. The latest deal connects Astellas to NuMedii, a digital drug discovery shop cofounded by Atul Butte that lists Allergan among its clients.

NIH urged to 'break taboo' against using its power to bypass drug patents

The National Institutes of Health (NIH) has said that it would take "extraordinary" circumstances for the agency to address rising drug prices, even as skyrocketing costs draw criticism from patients, payers and the public. But two organizations think that it's about time for the NIH to act. And they're not mincing words with their request.

Astellas, Medivation report successful enzalutamide mCRPC PhII data in Lancet

The U.S. arm of Tokyo-based Astellas Pharma and U.S.-listed Medivation said enzalutamide met its primary endpoint in a Phase II study to treat metastatic castration-resistant prostate cancer (mCRPC).

The biggest winners--and losers--in the 2015 race for new drug approvals

In 2015, the FDA by its own account approved 45 new drugs, the largest one-year tally since 1996, which wrapped up with a record 53 regulatory OKs. Now, here's the full list of new drugs approved by the FDA in 2015, in chronological order.

Astellas strikes tech-enabled drug repositioning deal with Biovista

Astellas has turned to Biovista for help finding new indications for some of its existing compounds. The project is underpinned by Biovista's Clinical Outcome Search Space technology, a tool that combines literature searches and in silico modeling to spot links between drugs and targets.

Japan's Astellas Pharma gets $727M for ailing dermatology unit as it swings to new areas

Japan's Astellas Pharma sold its dermatology business to Danish specialty product firm LEO in a deal that will free up cash from a unit that analysts have long said is non-core and which follows a high profile move this week to splash out $379 million to buy U.S-based regenerative ophthalmology biotech Ocata Therapeutics.

Japan's Astellas adds to U.S. ops with regenerative biotech acquisition

Japan's Astellas Pharma said it is paying $379 million in case to buy Ocata Therapeutics, a biotechnology cmpany that specializes in regenerative drugs to treat macular degeneration, according to a report by the  Boston Globe.

Astellas offers $379M buyout for a pioneering stem cell survivor

Astellas Pharma has stepped up with a $379 million bid for Ocata Therapeutics, a pioneering--and often controversial--stem cell company that has managed to survive a years-long roller coaster ride through the hype, hope and disappointments of the past decade.

Astellas says stem cell research promising on kidney failure

Astellas Pharma and Japan university researchers say they have succeeded with preclinical work showing that induced pluripotent stem cells are capable of improving the symptoms of kidney failure.